Clinical Trial Update: A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.25/500mg in Healthy Male Volunteers [Phase 1]

View source ↗

Summary

This update notes the completion of a Phase 1 pharmacokinetic study of CKD-395 (0.25/500 mg) in healthy male volunteers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• CKD-395 (CKD-395)

Snippet

Sponsor: Chong Kun Dang Pharmaceutical | Conditions: Diabetes Mellitus, Type II | Phase 1 | Status: COMPLETED